GxP Data Integrity: ALCOA+ and Data Governance in Regulated Environments
Data Integrity — the assurance that GxP data is complete, consistent, accurate, and unaltered throughout its lifecycle — has become one of the foremost priorities of international regulatory authorities.
The ALCOA+ Principles: Foundation of GxP Data Integrity
ALCOA — originally codified by the FDA — defines five fundamental attributes that every GxP data record must possess:
- Attributable: data must be unambiguously traceable to the person or system that generated or modified it.
- Legible: data must be readable, permanent, and unalterable.
- Contemporaneous: data must be recorded at the time the activity occurs, not retrospectively.
- Original: the original record — the raw data — must be preserved and accessible.
- Accurate: data must faithfully reflect the observed or measured reality.
The “+” of ALCOA+ adds four complementary attributes: Complete, Consistent, Enduring, Available.
The Regulatory Framework
MHRA Data Integrity Definitions and Guidance for Industry (2018) — the most operationally detailed international Data Integrity guidance, widely recognized as international best practice.
WHO Technical Report 1010, Annex 4 (2022) — updated WHO framework for pharmaceutical data integrity governance.
FDA Guidance for Industry: Data Integrity and Compliance With Drug CGMP (2018) — the FDA’s Q&A format guidance addressing complete data definition, chromatographic raw data, standalone systems, backup, and error management.
EudraLex Annex 11 — contains directly relevant requirements: automated audit trails, data protection, access control, and periodic data integrity verification.
ISPE GAMP 5 Good Practice Guide: Data Integrity — Key Concepts (2022) — practical framework for implementing Data Integrity principles in GxP computerized systems.
Audit Trail Review
Configuring a compliant audit trail is necessary but not sufficient — regular review by qualified personnel is itself a GxP requirement. An adequate audit trail review covers: data modifications in production and analytical systems, unauthorized or failed login attempts, system configuration changes, instrument parameter modifications, off-hours operations, and sequence anomalies.
Data Flow Mapping
Data flow mapping traces the path of every GxP-relevant data element across the organization’s systems — from origin through intermediate processing and analysis to final archiving. It identifies critical Data Integrity vulnerability points: manual transcription steps, non-validated system interfaces, unconnected standalone systems, data stored in unprotected formats.
Raw Data Management
Raw data — original, unprocessed data — is the central object of Data Integrity requirements. MHRA and FDA guidance are explicit: raw data must be retained in its original form, accessible, readable, and protected from modification.
Our Service: Gap Assessment, Remediation, and Data Governance
Gap Assessment: three-phase structured evaluation covering discovery (system/data flow inventory, existing SOPs, key personnel interviews), technical and regulatory assessment against ALCOA+/MHRA/WHO/FDA requirements, and production of a Gap Report with a concrete, actionable Remediation Plan.
Data Governance Program: beyond immediate remediation, sustainable Data Integrity requires a governance architecture: updated policies and SOPs, continuous training, Data Integrity KPIs, risk-based audit trail review program, periodic self-inspection, and an organizational culture of data integrity.
Why Dalia IA
- 20+ years of GxP pharmaceutical and life sciences experience
- Deep expertise in MHRA, WHO TRS 1010, FDA 2018, Annex 11
- Experience with electronic, paper, and hybrid systems
- Complete data flow mapping capability across multi-system environments
- Track record building sustainable Data Governance programs
- Inspection-ready deliverables for FDA, EMA, MHRA, AIFA
Domande frequenti
What is GxP Data Integrity in the pharmaceutical industry?
GxP Data Integrity is the assurance that scientific, manufacturing, and clinical data is complete, accurate, consistent, and unaltered throughout its lifecycle. The foundational principles are captured in the ALCOA+ acronym, required by MHRA, WHO TRS 1010, FDA 2018, and EudraLex Annex 11.
What are the key international Data Integrity guidance documents?
The principal guidance documents are: MHRA Data Integrity Guidance (2018), WHO Technical Report 1010 Annex 4 (2022), FDA Guidance "Data Integrity and Compliance With Drug CGMP" (2018), and EudraLex Annex 11 (EU).
What is raw data and why does it matter for Data Integrity?
Raw data is the original, unprocessed data in the form generated by the instrument or system, before any processing or calculation. It must be retained in its original form, accessible and unalterable.
What does a Data Integrity gap assessment typically cover?
A comprehensive Data Integrity gap assessment covers: electronic system configurations (audit trail, access control, backup), hybrid system interfaces, standalone systems, raw data management, audit trail review procedures, personnel training, and organizational practices for OOS/OOT management.
What is the difference between a Data Integrity remediation plan and a Data Governance program?
A remediation plan addresses specific, identified gaps with concrete corrective actions. A Data Governance program is a broader, ongoing framework that sustains Data Integrity over time: updated SOPs, training programs, periodic KPI monitoring, self-inspection programs, and an organizational culture of data integrity.